{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:02:54Z","timestamp":1760148174382,"version":"build-2065373602"},"reference-count":28,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Rocky Vista University"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Calcific aortic valve disease (CAVD) is a debilitating condition for which there are limited therapeutic options aside from valve replacement. As such, it is crucial to explore alternative management strategies for CAVD. Non-steroidal anti-inflammatory drugs (NSAIDs), particularly celecoxib, have been the subject of debate in the literature regarding their potential impact on CAVD. We conducted an in-depth analysis of five studies exploring the effect of celecoxib on CAVD and found discrepancies in both methods and results. Our findings suggest that celecoxib may impact the development of this disease via multiple mechanisms, each of which may have different effects on its pathogenesis. We also discovered limited clinical research examining the connection between celecoxib use and CAVD in medical patients. As such, further studies are needed to clarify the role of celecoxib and other NSAIDs in CAVD progression in order to inform future treatment options and clarify their impact on the disease.<\/jats:p>","DOI":"10.3390\/jcm12072717","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T05:42:44Z","timestamp":1680673364000},"page":"2717","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Effect of Celecoxib on the Progression of Calcific Aortic Valve Disease\u2014Protective or Pathogenic?"],"prefix":"10.3390","volume":"12","author":[{"given":"Zachary","family":"Vinton","sequence":"first","affiliation":[{"name":"College of Osteopathic Medicine, Rocky Vista University, Parker, CO 80112, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0458-2147","authenticated-orcid":false,"given":"Kevin","family":"Wolfe","sequence":"additional","affiliation":[{"name":"College of Osteopathic Medicine, Rocky Vista University, Parker, CO 80112, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jensen","family":"Fisher","sequence":"additional","affiliation":[{"name":"Department of Library Services, Rocky Vista University, Parker, CO 80112, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9785-5969","authenticated-orcid":false,"given":"Amanda","family":"Brooks","sequence":"additional","affiliation":[{"name":"Office of Research and Scholarly Activity, Rocky Vista University, Parker, CO 80112, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"685","DOI":"10.3389\/fphar.2020.00685","article-title":"Calcific Aortic Valve Disease-Natural History and Future Therapeutic Strategies","volume":"11","author":"Alushi","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"16006","DOI":"10.1038\/nrdp.2016.6","article-title":"Calcific aortic stenosis","volume":"2","author":"Lindman","year":"2016","journal-title":"Nat. Rev. Dis. Primer."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"12710","DOI":"10.18632\/aging.202942","article-title":"Changing epidemiology of calcific aortic valve disease: 30-year trends of incidence, prevalence, and deaths across 204 countries and territories","volume":"13","author":"Yi","year":"2021","journal-title":"Aging"},{"unstructured":"Pujari, S.H., and Agasthi, P. (2022, January 06). Aortic Stenosis, StatPearls, Available online: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557628\/.","key":"ref_4"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1161\/CIRCULATIONAHA.110.006767","article-title":"Calcific Aortic Valve Disease: Not Simply a Degenerative Process A Review and Agenda for Research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group","volume":"124","author":"Rajamannan","year":"2011","journal-title":"Circulation"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1161\/CIRCULATIONAHA.104.486738","article-title":"Spectrum of Calcific Aortic Valve Disease: Pathogenesis, Disease Progression, and Treatment Strategies","volume":"111","author":"Freeman","year":"2005","journal-title":"Circulation"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1161\/ATVBAHA.108.176347","article-title":"Altered shear stress stimulates upregulation of endothelial VCAM-1 and ICAM-1 in a BMP-4- and TGF-beta1-dependent pathway","volume":"29","author":"Sucosky","year":"2009","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.clim.2006.01.016","article-title":"Prostaglandin E2 synthesis and secretion: The role of PGE2 synthases","volume":"119","author":"Park","year":"2006","journal-title":"Clin. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1007\/s000110050284","article-title":"Anti-inflammatory drugs and their mechanism of action","volume":"47","author":"Vane","year":"1998","journal-title":"Inflamm. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1172\/JCI27291","article-title":"Biological basis for the cardiovascular consequences of COX-2 inhibition: Therapeutic challenges and opportunities","volume":"116","author":"Grosser","year":"2006","journal-title":"J. Clin. Investig."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.yjmcc.2003.09.015","article-title":"Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification","volume":"36","author":"Kaden","year":"2004","journal-title":"J. Mol. Cell Cardiol."},{"doi-asserted-by":"crossref","unstructured":"Weiss, R.M., Lund, D.D., Chu, Y., Brooks, R.M., Zimmerman, K.A., El Accaoui, R., Davis, M.K., Hajj, G.P., Zimmerman, M.B., and Heistad, D.D. (2013). Osteoprotegerin Inhibits Aortic Valve Calcification and Preserves Valve Function in Hypercholesterolemic Mice. PLoS ONE, 8.","key":"ref_12","DOI":"10.1371\/journal.pone.0065201"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.jacc.2015.05.066","article-title":"Calcification in Aortic Stenosis: The Skeleton Key","volume":"66","author":"Pawade","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.atherosclerosis.2012.10.055","article-title":"Angiotensin II promotes aortic valve thickening independent of elevated blood pressure in apolipoprotein-E deficient mice","volume":"226","author":"Fujisaka","year":"2013","journal-title":"Atherosclerosis"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.jacc.2006.11.043","article-title":"Angiotensin receptor-1 blocker inhibits atherosclerotic changes and endothelial disruption of the aortic valve in hypercholesterolemic rabbits","volume":"49","author":"Arishiro","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1053\/j.semtcvs.2013.09.002","article-title":"Transcatheter aortic valve replacement: Current status and future directions","volume":"25","author":"Desai","year":"2013","journal-title":"Semin. Thorac. Cardiovasc. Surg."},{"key":"ref_17","first-page":"e72","article-title":"2020 ACC\/AHA Guideline for the Management of Patients with Valvular Heart Disease: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"143","author":"Otto","year":"2021","journal-title":"Circulation"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1161\/ATVBAHA.114.305159","article-title":"COX2 Inhibition Reduces Aortic Valve Calcification In Vivo","volume":"35","author":"Wirrig","year":"2015","journal-title":"Arterioscler Thromb. Vasc. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jacbts.2018.12.003","article-title":"Celecoxib Is Associated With Dystrophic Calcification and Aortic Valve Stenosis","volume":"4","author":"Bowler","year":"2019","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/s41569-020-0366-z","article-title":"Cardiovascular effects and safety of (non-aspirin) NSAIDs","volume":"17","author":"Schjerning","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"doi-asserted-by":"crossref","unstructured":"Sega, F.V.D., Fortini, F., Cimaglia, P., Marracino, L., Tonet, E., Antonucci, A., Moscarelli, M., Campo, G., Rizzo, P., and Ferrari, R. (2020). COX-2 Is Downregulated in Human Stenotic Aortic Valves and Its Inhibition Promotes Dystrophic Calcification. Int. J. Mol. Sci., 21.","key":"ref_21","DOI":"10.3390\/ijms21238917"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.atherosclerosis.2013.05.002","article-title":"Associations between Aspirin and other non-steroidal anti-inflammatory drugs and aortic valve or coronary artery calcification: The Multi-Ethnic Study of Atherosclerosis and the Heinz Nixdorf Recall Study","volume":"229","author":"Delaney","year":"2013","journal-title":"Atherosclerosis"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"107194","DOI":"10.1016\/j.carpath.2019.107194","article-title":"Induction of aortic valve calcification by celecoxib and its COX-2 independent derivatives is glucocorticoid-dependent","volume":"46","author":"Vaidya","year":"2020","journal-title":"Cardiovasc. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.bone.2008.08.109","article-title":"COX-2 from the injury milieu is critical for the initiation of periosteal progenitor cell mediated bone healing","volume":"43","author":"Xie","year":"2008","journal-title":"Bone"},{"key":"ref_25","first-page":"831","article-title":"Selective COX-2 inhibitors, NSAIDs and cardiovascular events\u2014Is celecoxib the safest choice?","volume":"3","author":"Howes","year":"2007","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1161\/ATVBAHA.112.300278","article-title":"Cadherin-11 regulates cell-cell tension necessary for calcific nodule formation by valvular myofibroblasts","volume":"33","author":"Hutcheson","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/cpt.2613","article-title":"The Impact of CYP2C9*11 Allelic Variant on the Pharmacokinetics of Phenytoin and (S)-Warfarin","volume":"112","author":"Wanounou","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00008571-200308000-00005","article-title":"Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites","volume":"13","author":"Kirchheiner","year":"2003","journal-title":"Pharmacogenetics"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/7\/2717\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:10:22Z","timestamp":1760123422000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/7\/2717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,5]]},"references-count":28,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["jcm12072717"],"URL":"https:\/\/doi.org\/10.3390\/jcm12072717","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2023,4,5]]}}}